BioPharmSignal logoBioPharmSignal

Biotech News

Legend Biotech to Host Investor Conference Call on Third Quarter 2026 Results

Legend Biotech Corporation (LEGN)Legend Biotech CorporationEarnings

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 a.m. ET on Tuesday, November 10, 2026, to review third quarter 2026 financial results.

Related news

SNDXSyndax Pharmaceuticals2026-10-26 11:00 EST

Syndax to Announce Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 2, 2026

COGTCogent Biosciences2026-11-05 21:02 EST

Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2026 Financial Results

RVMDRevolution Medicines2026-11-04 21:02 EST

Revolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate Progress

URGNUroGen Pharma2026-11-04 13:00 EST

UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights

KURAKura Oncology2026-11-03 11:58 EST

Kura Oncology to Report Third Quarter Financial Results on November 10

IDYAIDEAYA Biosciences2026-11-03 11:00 EST

IDEAYA Biosciences Reports Financial Results for the Third Quarter 2026 and Provides a Business Update

BMYBMYBristol-Myers Squibb Company2026-10-29 10:59 EST

Bristol Myers Squibb Reports Third Quarter Financial Results for 2026

RLAYRelay Therapeutics2026-10-28 20:12 EST

Relay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026

URGNUroGen Pharma2026-10-27 22:00 EST

UroGen Pharma to Report Third Quarter 2026 Financial Results on Wednesday, November 4th, 2026

CHRSCoherus BioSciences, Inc.2026-10-26 13:30 EST

Coherus Oncology to Report Third Quarter 2026 Financial Results on November 9, 2026

View all latest news

Legend Biotech Corporation

Global Cell Therapy Company Legend Biotech develops and commercializes cell therapies for cancer and other serious diseases. CARVYKTI CARVYKTI, or ciltacabtagene autoleucel, is a one-time BCMA-directed CAR T-cell therapy for multiple myeloma developed and commercialized with Johnson & Johnson. Global Manufacturing and Access Legend...

Recent company news

LEGNLegend Biotech Corporation2026-11-04 14:00 EST

Legend Biotech to Showcase CARVYKTI® Leadership and Next-Generation Cell Therapy Innovation at ASH 2026

LEGNLegend Biotech Corporation2026-10-27 12:00 EST

Legend Biotech to Host Investor Conference Call on Third Quarter 2026 Results

LEGNLegend Biotech Corporation2026-10-15 12:00 EST

Legend Biotech Announces U.S. FDA Clearance of IND Application for LB2501, an Investigational CD19/CD20 In Vivo CAR-T Therapy

LEGNLegend Biotech Corporation2026-10-01 13:00 EST

Legend Biotech Launches Inaugural ELITE Grant Program to Advance the Next Generation of CAR-T Innovation in Multiple Myeloma

LEGNLegend Biotech Corporation2026-09-25 11:00 EST

Legend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusion

Stock data

Close
22.54 USD
Market cap
6.74B USD
Exchange
NASDAQ
Sector
CAR-T Therapy, TCR-T Therapy, Antibody Drugs, ADCs, Biopharma
Location
United States